CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
BN101drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04930562
NCT04930562Phase 2Completed
CompareCT.gov

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of BN101 in Subject With Chronic Graft Versus Host Disease (cGVHD) After at Least Fist Line of Systemic Therapy

BioNova Pharmaceuticals (Shanghai) LTD.·interventional·Posted Jun 18, 2021·Updated Jan 17, 2024

In Brief

A Phase 2 clinical trial evaluating BN101 for GVHD, Chronic. Completed, enrolled 30 participants across 7 sites.

Detailed Summary

This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGVHD, Chronic
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJun 18, 2021
Enrollment StartApr 27, 2021
Primary CompletionJun 10, 2022
Study CompletionDec 10, 2022
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.0 years ago

Interventions

BN101drug

BN101 is an orally ROCK2 selective inhibitor